These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36963656)

  • 1. Pre-Omicron seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and teenagers in Montréal, Canada.
    Zinszer K; Charland K; Pierce L; Saucier A; McKinnon B; Hamelin MÈ; Cheriet I; Da Torre MB; Carbonneau J; Nguyen CT; De Serres G; Papenburg J; Boivin G; Quach C
    Int J Infect Dis; 2023 Jun; 131():119-126. PubMed ID: 36963656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada.
    Zinszer K; McKinnon B; Bourque N; Pierce L; Saucier A; Otis A; Cheriet I; Papenburg J; Hamelin MÈ; Charland K; Carbonneau J; Zahreddine M; Savard A; Fortin G; Apostolatos A; Haley N; Ratté N; Laurin I; Nguyen CT; Conrod P; Boivin G; De Serres G; Quach C
    JAMA Netw Open; 2021 Nov; 4(11):e2135975. PubMed ID: 34812845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays.
    Tuite AR; Fisman D; Abe KT; Rathod B; Pasculescu A; Colwill K; Gingras AC; Yi QL; O'Brien SF; Drews SJ
    Microbiol Spectr; 2022 Feb; 10(1):e0256321. PubMed ID: 35196819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools.
    Ulyte A; Radtke T; Abela IA; Haile SR; Berger C; Huber M; Schanz M; Schwarzmueller M; Trkola A; Fehr J; Puhan MA; Kriemler S
    BMJ; 2021 Mar; 372():n616. PubMed ID: 33731327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022.
    Briggs J; Takahashi S; Nayebare P; Cuu G; Rek J; Zedi M; Kizza T; Arinaitwe E; Nankabirwa JI; Kamya M; Jagannathan P; Jacobson K; Rosenthal PJ; Dorsey G; Greenhouse B; Ssewanyana I; Rodríguez-Barraquer I
    JAMA Netw Open; 2023 Feb; 6(2):e2255978. PubMed ID: 36790811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic.
    Anand S; Montez-Rath M; Han J; Cadden L; Hunsader P; Kerschmann R; Beyer P; Boyd SD; Garcia P; Dittrich M; Block GA; Parsonnet J; Chertow GM
    JAMA Netw Open; 2021 Jul; 4(7):e2116572. PubMed ID: 34251441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study.
    Suntronwong N; Vichaiwattana P; Klinfueng S; Puenpa J; Kanokudom S; Assawakosri S; Chansaenroj J; Srimuan D; Thatsanatorn T; Songtaisarana S; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
    PLoS One; 2023; 18(4):e0279147. PubMed ID: 37104299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
    Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
    JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
    Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
    Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.
    Lalwani P; Araujo-Castillo RV; Ganoza CA; Salgado BB; Pereira Filho IV; da Silva DSS; de Morais TBDN; Jordão MF; Ortiz JV; Barbosa ARC; Sobrinho WBS; Cordeiro IB; de Souza Neto JN; de Assunção EN; da Costa CF; de Souza PE; de Albuquerque BC; Astofi-Filho S; ; Lalwani JDB
    Lancet Glob Health; 2021 Nov; 9(11):e1508-e1516. PubMed ID: 34678195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of anti-SARS-CoV-2 antibodies among children and their parents in Greece.
    Dimopoulou D; Kyritsi M; Dadouli K; Vergadi E; Tsiligianni E; Papadimitriou E; Mavridi A; Giannakopoulos S; Tsiourvopoulou G; Palyvou M; Angeli E; Brikos N; Eleftheriou I; Spoulou V; Michos A; Gkentzi D; Siomou E; Papaevangelou V; Grivea I; Syrogiannopoulos G; Galanakis E; Hadjichristodoulou C; Tsolia M
    Eur J Pediatr; 2023 Jan; 182(1):439-449. PubMed ID: 36383284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cohort study measuring SARS-CoV-2 seroconversion and serial viral testing in university students.
    Lee CC; Segaloff HE; Cole D; Rosenblum HG; Morgan CN; Somers T; Desamu-Thorpe R; Foster MA; Currie D; Ruff J; Payne D; Whyte TJ; Abedi GR; Bigouette JP; Kahrs J; Langolf K; Remington P; Sterkel A; Kelly P; Westergaard RP; Bateman AC; Hsu CH; Tate JE; Kirking HL
    BMC Infect Dis; 2022 Mar; 22(1):314. PubMed ID: 35361140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Seroconversion in Children and Adults With Mild COVID-19.
    Toh ZQ; Anderson J; Mazarakis N; Neeland M; Higgins RA; Rautenbacher K; Dohle K; Nguyen J; Overmars I; Donato C; Sarkar S; Clifford V; Daley A; Nicholson S; Mordant FL; Subbarao K; Burgner DP; Curtis N; Bines JE; McNab S; Steer AC; Mulholland K; Tosif S; Crawford NW; Pellicci DG; Do LAH; Licciardi PV
    JAMA Netw Open; 2022 Mar; 5(3):e221313. PubMed ID: 35262717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States.
    Levorson RE; Christian E; Hunter B; Sayal J; Sun J; Bruce SA; Garofalo S; Southerland M; Ho S; Levy S; Defillipi C; Peake L; Place FC; Hourigan SK
    PLoS One; 2021; 16(11):e0259823. PubMed ID: 34748615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of SARS-CoV-2 Alpha (B.1.1.7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: Active prospective surveillance, December 2020 to March 2021, England.
    Ladhani SN; Ireland G; Baawuah F; Beckmann J; Okike IO; Ahmad S; Garstang J; Brent AJ; Brent B; Aiano F; Amin-Chowdhury Z; Kall M; Borrow R; Linley E; Zambon M; Poh J; Warrener L; Lackenby A; Ellis J; Amirthalingam G; Brown KE; Ramsay ME
    J Infect; 2021 Nov; 83(5):573-580. PubMed ID: 34400220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests.
    van Dam P; Huizing M; Roelant E; Hotterbeekx A; De Winter FHR; Kumar-Singh S; Moons P; Amajoud Z; Vulsteke C; Croes L; Janssens A; Berneman Z; Prenen H; Meuris L; Vanden Berghe W; Smits E; Peeters M
    Eur J Cancer; 2021 May; 148():328-339. PubMed ID: 33773276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the Cumulative Incidence of SARS-CoV-2 Infection and the Infection Fatality Ratio in Light of Waning Antibodies.
    Shioda K; Lau MSY; Kraay ANM; Nelson KN; Siegler AJ; Sullivan PS; Collins MH; Weitz JS; Lopman BA
    Epidemiology; 2021 Jul; 32(4):518-524. PubMed ID: 33935138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.